New combo therapy aims to boost survival in kids with aggressive lymphoma

NCT ID NCT07168980

Recruiting now Disease control Sponsor: Children's Cancer Group, China Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 17, 2026 · Updated 32 times

Summary

This study tests whether giving a powerful chemotherapy along with early and frequent doses of the targeted drug rituximab can help children and teenagers with aggressive B-cell non-Hodgkin lymphoma live longer without the cancer coming back. About 87 participants will receive this combination, and their outcomes will be compared to a previous study. The goal is to improve event-free survival and overall survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Shanghai Children's Medical Center
RECRUITING

Shanghai, Shanghai Municipality, 201315, China

Conditions

The condition(s) this trial relates to.

B-cell non-Hodgkin lymphoma Burkitt lymphoma diffuse large B-cell lymphoma primary mediastinal large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MATURE B-CELL NON-HODGKIN LYMPHOMA